Cyclerion Therapeutics, Inc. (KRSA) vs Xencor, Inc. (XNCR)
Cyclerion Therapeutics, Inc. and Xencor, Inc. are both Biotechnology companies. Cyclerion Therapeutics, Inc. and Xencor, Inc. are of similar size ($1.8B and $1.7B). Cyclerion Therapeutics, Inc. grew revenue faster over the last twelve months: 30.8% against −28.6%. Cyclerion Therapeutics, Inc. has the higher net margin (0.00% vs −155.6%) and the higher return on invested capital (−115.4% vs −288.7%). Across the 16 metrics below, Cyclerion Therapeutics, Inc. leads on 8 and Xencor, Inc. on 8.
Valuation
Profitability
| Metric | KRSA | XNCR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (205.84%) | 0.00% |
| Net margin | 0.00% | (155.59%) | 0.00% |
| Free cash flow margin | 0.00% | (198.42%) | 0.00% |
| Return on equity | (98.22%) | (29.07%) | (57.72%) |
| Return on assets | (82.29%) | (20.36%) | (49.22%) |
| Return on invested capital | (115.40%) | (288.71%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack